# 3T MRI Biomarkers of Glioma Treatment Response

> **NCT01996527** · EARLY_PHASE1 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Recurrent Adult Brain Tumor

## Interventions

- **DEVICE:** 3-Tesla magnetic resonance imaging
- **DEVICE:** CEST-MRI
- **DEVICE:** DW-MRI
- **DEVICE:** DCE-MRI
- **DEVICE:** DSC-MRI
- **DRUG:** IV administration of gadolinium-containing contrast agent

## Key facts

- **NCT ID:** NCT01996527
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2015-11-23
- **Final completion:** 2016-01-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** PI left institution
- **Last updated:** 2017-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01996527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01996527, "3T MRI Biomarkers of Glioma Treatment Response". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01996527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*